SHAILY Shaily Engineering Plastics Q4 FY26 results (Jan–Mar 2026) and concall
Shaily Engineering Plastics reported strong Q4 FY26 results driven by robust healthcare segment growth and margin expansion. The company achieved significant milestones with the commercial launch of Semaglutide pen injectors in global markets and entry into the semiconductor supply chain. However, the consumer segment faced headwinds due to weaker market demand. Management is focused on scaling new capacities and diversifying into high-growth verticals, while maintaining confidence in sustainable and improving margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 10.3%, net profit up 63.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 180 | 186 | 203 | 225 | 236 +31% | 236 +27% | 224 +10% |
| EBITDA | 31 | 38 | 48 | 61 | 68 +119% | 64 +68% | 63 +31% |
| Net profit | 13 | 18 | 30 | 36 | 41 +215% | 36 +100% | 49 +63% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





